

IN THE CLAIMS:

Please rewrite the pending claims as follows:

53. (previously presented) An anticode oligomer complementary to bcl-2 mRNA consisting of from 18-35 bases and comprising the nucleotide sequence TCTCCCAGCGTGCGCCAT (SEQ ID NO:17).

70. (previously presented) An anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary to a portion of SEQ ID NO:19.

71. (previously presented) An anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary to a portion of SEQ ID NO:22.

72. (previously presented) The anticode oligomer of Claim 70, wherein said anticode oligomer is an antisense oligonucleotide complementary to a splice acceptor site of SEQ ID NO:19.

73. (previously presented) The anticode oligomer of Claim 71, wherein said anticode oligomer is an antisense oligonucleotide complementary to a splice donor site of SEQ ID NO:22.

74. (previously presented) The anticode oligomer of Claim 70, wherein said anticode oligomer is 10 to 40 bases in length and is complementary to a 5'-untranslated region of SEQ ID NO:19.

75. (previously presented) A composition comprising the anticode oligomer of Claims 53, 70, 71, 72, 73 or 74; and a pharmaceutically acceptable carrier.

76. (previously presented) The anticode oligomer of Claim 53, wherein said anticode oligomer contains at least one phosphorothioate-modified nucleotide.

77. (previously presented) A composition comprising the anticode oligomer of Claim 76; and a pharmaceutically acceptable carrier.

78. (previously presented) The anticodon oligomer of Claim 76, wherein said anticodon oligomer is a phosphodiester/phosphorothioate chimera.

79. (previously presented) The anticodon oligomer of Claim 76 wherein the oligonucleotide comprises at least 2 to 3 phosphorothioate linkages.

80. (previously presented) A composition comprising the anticodon oligomer of Claim 78 or 79; and a pharmaceutically acceptable carrier.

81. (previously presented) The anticodon oligomer of Claim 53, wherein said anticodon oligomer contains at least one phosphoramidate-modified nucleotide.

82. (previously presented) The anticodon oligomer of Claim 70, 71, 72, 73 or 74, wherein said anticodon oligomer contains at least one phosphorothioate-modified nucleotide.

83. (previously presented) A composition comprising the anticodon oligomer of Claim 82; and a pharmaceutically acceptable carrier.

84. (previously presented) The anticodon oligomer of Claim 82, wherein said anticodon oligomer is a phosphodiester/phosphorothioate chimera.

85. (previously presented) The anticodon oligomer of Claim 84 wherein the oligonucleotide comprises at least 2 to 3 phosphorothioate linkages.

86. (previously presented) A composition comprising the anticodon oligomer of Claim 84 and a pharmaceutically acceptable carrier.

87. (previously presented) A composition comprising the anticodon oligomer of Claim 85 and a pharmaceutically acceptable carrier.

88. (previously presented) The anticodon oligomer of Claim 70, 71, 72, 73 or 74, wherein said anticodon oligomer contains at least one phosphoramidate-modified nucleotide.